Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam plus aztreonam against MBL-producing Klebsiella pneumoniae
PACTR202410744344899Completed
- Sponsor
- Suez Canal University Hospital
- Start
- Dec 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ceftazidime + avibactam and aztreonam in Klebsiella pneumoniae infection (2 arms), sponsored by Suez Canal University Hospital. Primary endpoint: Isolation and identification of Klebsiella pneumoniae. Started Dec 2022; status: completed.
02
Drugs
ceftazidime + avibactamaztreonam
03
Conditions
Klebsiella pneumoniae infection
Beyond the preview
Go deeper on PACTR202410744344899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410744344899.